ǥ :
|
ȣ - 550436 60 |
Clinical Outcomes and Its Risk Factors of Patients with Peri-Stent Contrast Staining after Sirolimus-Eluting Stent Implantation |
영남대학교 병원 순환기내과 |
김유민, 박종선, 강상욱, 박원종, 강민규, 김웅, 이상희, 홍그루, 신동구, 김영조 |
Background
Peri-Stent Contrast Staining (PSS) could be regarded as a relatively severe form of incomplete stent apposition. The aim of this study is to evaluate their incidence, risk factor and clinical outcomes.
Materials and Methods
From April 2005 to August 2008, 561 consecutive patients with 898 lesions that were treated with Sirolimus-Eluting Stent (SES) and were evaluated by follow up angiography at 10 months. The patients were divided according to with PSS (Group 1, n=23) and without it (Group 2, n=538). Major adverse cardiac events (MACE) for 3years such as cardiac death, myocardial infarction(MI), target lesion revascularization (TLR), target artery revascularization (TVR) were evaluated. Independent risk factor for PSS were elucidated by multivariate regression analysis.
Results
Baseline characteristics were not different. Mean follow-up duration was 937±146 days. It was not statistically significant that cumulative MACE for 1year found 8.7% in Group 1 and 5.9% in Group 2 ( p=0.643). But, Cumulative incidence of 3years MACE was found 39.1% in Group 1 and 15.6% in Group 2 ( p=0.007 ). There was no difference in stent thrombosis between two groups for 3years ( 5.9% in Group 1 vs. 4.1% in Group 2, p=0.517). Independent risk factor of PSS was total stent length >26mm ( p=0.028, OR 2.622, C.I.1.10 to 6.19).
Conclusions
Long term clinical outcome of patients with PSS might be worse than those without PSS. More large clinical study will be needed.
Key words : Peri-stent contrast staining, MACE, Sirolimus-Eluting Stent
|
|
|
|